Abstract: 16
The spike (S) protein of the recently emerged human coronavirus (MERS-CoV) mediates 17 infection by binding to the cellular receptor dipeptidyl peptidase 4 (DPP4). Here we mapped the 18 receptor-binding domain in the S protein to a 231-amino acid fragment (residues 358-588) by 19 evaluating the interaction of spike truncation variants with receptor expressing cells and soluble 20 DPP4. Antibodies to this domain -much less so to the preceding N-terminal region -efficiently 21 neutralize MERS-CoV infection. 22 23 Text 24
Just 10 years following the outbreak of the severe respiratory acute syndrome coronavirus 25 (SARS-CoV) the world is confronted with yet another deadly human coronavirus. The virus, first 26 provisionally called human coronavirus-EMC (hCoV-EMC) (1, 2) but now named MERS-CoV, 27 referring to its emergence in the Middle-East and to the respiratory syndrome it causes, 28 belongs to the betacoronavirus genus lineage 2c (3). As of June 7 th 2013, 55 cases have been 29 laboratory confirmed including 31 deaths, all from -or linked to -the Arabian Peninsula (4). Like 30 with SARS-CoV, patients affected by MERS-CoV suffer from severe and often lethal lower 31 respiratory tract infection. The epidemiology of MERS-CoV is still enigmatic, but the 32 geographical distribution of epidemiologically unlinked individuals points to intermittent, 33 zoonotic transmission from a -so far unknown -animal source, whereas a number of reported 34 clusters indicate limited human-to-human spread (5). 35
The main determinant of coronavirus tropism is the viral spike (S) protein as it mediates 36 binding to a cell-surface receptor. The MERS-CoV S protein, a 1353 amino acid type I 37 membrane glycoprotein, assembles into trimers that constitute the spikes or peplomers on the 38 surface of the enveloped coronavirus particle. The protein combines the two essential entry 39 functions, namely that of host receptor binding and membrane fusion, which are attributed to 40 the N-terminal (S1, residues 1-751) and C-terminal (S2, residues 752-1353) half of the S 41 protein, respectively ( Fig.1a ). Recently we have identified dipeptidyl peptidase 4 (DPP4, also 42 known as CD26), expressed in the human lung, as a functional receptor for MERS-CoV(6). 43 Importantly, MERS-CoV can also use the evolutionary conserved DPP4 of other species, most 44 notably that of bats(6, 7). 45
Coronaviruses bind to receptors via independently folded, generally about 150-300 46 residues long receptor binding domains (RBD) present in their S1 subunit, of which the location 47 within S1 can vary (8-10). Thus, for the betacoronavirus mouse hepatitis virus (MHV) the 48 binding to its CEACAM receptor (11) has been mapped to the N-terminal ~300 amino acids of 49 the spike protein (12, 13) whereas for the SARS-CoV -of the same genus -binding to the ACE2 50 receptor (14) maps to residues 323-502 of S1 (15, 16) ( Fig.1a ). Identification of the RBD can 51 hence help the development of monoclonal antibodies and vaccines for the treatment and 52 prevention of infection. The RBD is the most important target for neutralizing antibodies (12, 17, 53 18) preventing virus-receptor interaction. 54
We previously used the S1 domain of MERS-CoV fused to the Fc-region of human IgG to 55 demonstrate the interaction of S1 with DPP4-expressing cells and with soluble, i.e. non 56 membrane-anchored DPP4 (6). To identify the receptor binding domain in the MERS-CoV S1 57 subunit, we generated S1-Fc protein chimera´s with truncations at the C-terminus and 58 N-terminus of the S1 domain. We considered a three domain structure of the MERS-CoV S1 59 protein (residues 1-357, 358-588 and 589-747) based on the predicted location and structure of 60 the RBD of two other betacoronaviruses, MHV and SARS-CoV (12, 13, 15, 16), of which the 61 homologous regions for MERS-CoV S map to the residues 18-351 and 379-580, respectively 62 ( Fig.1b ). In addition, a soluble form of human DPP4 (residues 39-766) was made, which was 63 C-terminally tagged with the Fc region. These proteins were expressed in HEK-293T cells after 64 transfection of the respective expression plasmids and subsequently affinity-purified from the 65 cell culture supernatant using protein A sepharose beads as described(6). The Fc region of 66 purified sDPP4-Fc was proteolytically removed using trypsin (data not shown). First, we 67 analyzed the S1-Fc proteins and C-terminal S1 truncations thereof for their ability to interact 68 with sDPP4 using a co-purification assay. sDPP4 was efficiently co-purified by the S1-Fc 69 variants encompassing residues 1-588 and 1-747 whereas the 1-357 S1-Fc variant was unable 70 to bind sDPP4 ( Fig.2a ). We next generated an S1-Fc variant comprising residues 358-588, a 71 region homologous to the ACE2 receptor binding domain in SARS-CoV S1 (Fig.2a ). This S1-Fc 72 truncation variant efficiently bound soluble DPP4, indicating that the DPP4 receptor binding 73 domain is located within the 358-588 residues domain of the MERS-CoV spike protein. 74
We subsequently tested the ability of these S1-Fc variants to bind to HEK-293T cells 75 transiently expressing DPP4 by using flow cytometry. The S1-Fc variants encompassing 76 residues 1-588 and 358-588 bound to DPP4-expressing HEK-293T cells with efficiencies 77 comparable to the full-length S1 protein whereas no binding was observed with the 1-357 78 S1-Fc variant (Fig.2b) . These data show the 358-588 amino acids S1 region to be essential and 79 sufficient for binding to DPP4-expressing cells, consistent with the results of the sDPP4 80 interaction study. 81
To confirm the observed interactions in a more biological assay we analyzed the ability of 82 the S1-Fc variants to prevent MERS-CoV infection. Thus, Huh-7 cells were preincubated with 83 the different S1-Fc variants before being inoculated with the MERS-CoV. We found that the 84 variants encompassing residues 1-747 and 358-588, but not the 1-357 S1-Fc variant, inhibited 85 infection (Fig.2c) . 86
Finally polyclonal antibodies were raised in rabbits against the 1-747, 1-357 and 358-588 87 S1-Fc variants (Davids Biotechnology GmbH, Germany). The sera, which displayed equal 88 ELISA titers towards its antigen (1:300.000, data not shown), were tested for their ability to 89 neutralize virus infectivity. Antibodies raised against the 358-588 S1-Fc variant efficiently 90 neutralized virus infectivity, superior to those raised against the 1-747 and 1-357 S1-Fc variants 91 (Fig.2d ). This indicates that neutralizing epitopes within S1 are primarily localized to the RBD 92 region. The elicited antibodies are likely to block the interaction of the spike protein with DPP4 93 thereby neutralizing MERS-CoV infectivity. Of note, antibodies raised against the MERS-CoV-S 94 RBD did not cross-neutralize SARS-CoV infection (data not shown). The results demonstrate the 95 potential of S1 protein and of the 358-588 S1 polypeptide as subunit vaccines with a high 96 biosafety profile compared to vaccines based on inactivated viruses or live-attenuated virus. 97
Except for the betacoronavirus MHV, which binds to its CEACAM receptor through a 98 domain in the N-terminal part of its S1 protein, the RBDs of all other coronaviruses that engage 99 protein receptors and that have been mapped occur in the C-terminal portion of the S1 subunit 100 (Fig.3) . Examples also include the alphacoronaviruses binding to ACE2 (hCoV-NL63) and APN 101 (e.g. TGEV, hCoV-229E) (10, 19-25). In this study we have experimentally mapped the RBD of 102 MERS-CoV to a 231-amino acid fragment (residues 358-588) within the spike protein. This domain nicely corresponds with the S1 region recently anticipated to interact with the DPP4 104 receptor on the basis of theoretical S1 structure predictions (26). The RBD in the MERS-CoV 105 S1 protein localizes in the same region where the SARS-CoV S protein interacts with its ACE2 106 receptor (26).The SARS-CoV RBD structure displays a 5-stranded β-sheet core structure (β1-4 107 and MHV (strain A59) spike (S) protein sequence (drawn to scale) aligned at the S1-S2 junction. 118
The known receptor binding domain in the S1 subunit of MHV and SARS-CoV S proteins and 119 their corresponding homologous regions in hCoV-EMC S as defined by ClustalW alignment are 120 indicated. Positions of the transmembrane domain (yellow bar; predicted by the TMHMM server) 121 and of the predicted N-glycosylation sites (Ψ; predicted by the NetNGlyc server, only shown for 122 the hCoV-EMC S) are indicated. The border between the S1 and S2 subunits of the spike 123 protein is represented by a vertical white line. b, upper panel, schematic presentation of the 124 hCoV-EMC S1 subunit (residues 1-751) sequence. Cysteine positions in S1 subunit are 125 protein and efficiently elicits neutralizing antibodies. a, S1-Fc chimeric proteins and soluble 133 DPP4 (sDPP4) receptor were expressed from HEK-293T cells and purified from the culture 134 supernatant. S1-Fc proteinswere mixed with sDPP4 followed by protein A sepharose affinity 135 isolation, analyzed on a NoVEX® 4-12% Tris-Glycine gradient gel under non-reducing 136 conditions, and stained with GelCodeBlue reagent. Position of the S1-Fc proteins -running as 137 dimers under non-reducing conditions due to an Fc interchain disulphide bond -and sDPP4 as 138 well as the sizes of the marker proteins are indicated. Individual proteins were loaded as 139 controls. b, Binding of hCoV-EMC S1-Fc proteins to DPP4 expressing cells. 2.5x10 5 HEK-293T 140 cells transfected with control pCAGGS (grey shaded area) or with pCAGGS-DPP4 (black line) 141 expression plasmid were incubated with 15 μg/ml of the indicated S1-Fc followed by incubation 142 with DyLight488 labeled goat-anti-human IgG antibody and analysis by flow cytometry. An 143 Fc-chimera containing the S1 of infectious bronchitis virus (IBV-S1-Fc) was taken along as a 144 negative control. c, Inhibition of hCoV-EMC infection by S1-Fc 1-747, 1-357 and 358-588 145 variants. Huh7 cells were preincubated with 40 µg/ml S1- EMC-S1-1-357-Fc EMC-S1-Fc IBV-S1-Fc
